-
About UsBeijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs. -
R&D and ProductsPrimarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases. -
Investor RelationsGuided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
2018
July 15: The preparation of Phase III clinical trial samples for the hepatocyte growth factor naked plasmid injection has been completed.
October 12: The kickoff meeting for the Phase I multiple-dose clinical trial of recombinant human thymosin β4 for injection was held.
November 25: The investigator’s protocol discussion meeting for the Phase III clinical trial of recombinant human hepatocyte growth factor naked plasmid injection was held.
December 18: The signing ceremony for the company’s Series C funding round was held at Tasly Group.
Share to:
Friendly Links: Baidu | NORTHLAND
Contact Information
Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing
Follow Us
Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.
Web site
NL-BIO
NL003
NL005